268 related articles for article (PubMed ID: 11777999)
1. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.
Chandler WL; Jelacic S; Boster DR; Ciol MA; Williams GD; Watkins SL; Igarashi T; Tarr PI
N Engl J Med; 2002 Jan; 346(1):23-32. PubMed ID: 11777999
[TBL] [Abstract][Full Text] [Related]
2. The hemolytic-uremic syndrome--toxin, thrombin, and thrombosis.
Grabowski EF
N Engl J Med; 2002 Jan; 346(1):58-61. PubMed ID: 11778006
[No Abstract] [Full Text] [Related]
3. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
[TBL] [Abstract][Full Text] [Related]
4. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
[TBL] [Abstract][Full Text] [Related]
5. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome.
Nevard CH; Jurd KM; Lane DA; Philippou H; Haycock GB; Hunt BJ
Thromb Haemost; 1997 Dec; 78(6):1450-5. PubMed ID: 9423793
[TBL] [Abstract][Full Text] [Related]
6. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome.
Bergstein JM; Riley M; Bang NU
N Engl J Med; 1992 Sep; 327(11):755-9. PubMed ID: 1501651
[TBL] [Abstract][Full Text] [Related]
7. Escherichia coli O157:H7 as the predominant pathogen associated with the hemolytic uremic syndrome: a prospective study in the Pacific Northwest.
Neill MA; Tarr PI; Clausen CR; Christie DL; Hickman RO
Pediatrics; 1987 Jul; 80(1):37-40. PubMed ID: 3299236
[TBL] [Abstract][Full Text] [Related]
8. Soluble Fas and soluble Fas-ligand in children with Escherichia coli O157:H7-associated hemolytic uremic syndrome.
Masri C; Proulx F; Toledano B; Clermont MJ; Mariscalco MM; Seidman EG; Carcillo J
Am J Kidney Dis; 2000 Oct; 36(4):687-94. PubMed ID: 11007669
[TBL] [Abstract][Full Text] [Related]
9. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA
Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
11. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?
Itakura H; Sobel BE; Boothroyd D; Leung LL; Iribarren C; Go AS; Fortmann SP; Quertermous T; Hlatky MA;
Am Heart J; 2007 Dec; 154(6):1059-64. PubMed ID: 18035075
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota.
Smith KE; Wilker PR; Reiter PL; Hedican EB; Bender JB; Hedberg CW
Pediatr Infect Dis J; 2012 Jan; 31(1):37-41. PubMed ID: 21892124
[TBL] [Abstract][Full Text] [Related]
14. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.
Wong CS; Jelacic S; Habeeb RL; Watkins SL; Tarr PI
N Engl J Med; 2000 Jun; 342(26):1930-6. PubMed ID: 10874060
[TBL] [Abstract][Full Text] [Related]
15. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
Sartorio A; Cattaneo M; Bucciarelli P; Bottasso B; Porretti S; Epaminonda P; Faglia G; Arosio M
Exp Clin Endocrinol Diabetes; 2000; 108(7):486-92. PubMed ID: 11083070
[TBL] [Abstract][Full Text] [Related]
16. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
17. Elevated tissue factor circulating levels in children with hemolytic uremic syndrome caused by verotoxin-producing E. coli.
Kamitsuji H; Nonami K; Murakami T; Ishikawa N; Nakayama A; Umeki Y
Clin Nephrol; 2000 May; 53(5):319-24. PubMed ID: 11305804
[TBL] [Abstract][Full Text] [Related]
18. A cluster of Escherichia coli O157:H7 infections with the hemolytic-uremic syndrome and death in California. A mandate for improved surveillance.
Shefer AM; Koo D; Werner SB; Mintz ED; Baron R; Wells JG; Barrett TJ; Ginsberg M; Bryant R; Abbott S; Griffin PM
West J Med; 1996; 165(1-2):15-9. PubMed ID: 8855679
[TBL] [Abstract][Full Text] [Related]
19. Activation of coagulation and fibrinolytic systems in patients with CLI is not normalized after surgical revascularisation.
Pärsson H; Holmberg A; Siegbahn A; Bergqvist D
Eur J Vasc Endovasc Surg; 2004 Feb; 27(2):186-92. PubMed ID: 14718902
[TBL] [Abstract][Full Text] [Related]
20. Hemolytic uremic syndrome: an emerging health risk.
Razzaq S
Am Fam Physician; 2006 Sep; 74(6):991-6. PubMed ID: 17002034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
